Savient Pharmaceuticals appoints president of Savient Europe
David Veitch takes up the role
Veitch brings extensive commercial knowledge of the European Union across marketing, sales, market access and general management to the US biopharmaceutical firm. He will be responsible for establishing, building and leading Savient's European regional organisation to launch and drive the future growth of Krystexxa (pegloticase), a drug for the treatment of chronic gout in adult patients refractory to conventional therapy.
Savient submitted its European Marketing Authorisation Application (MAA) for Krystexxa in May 2011, and anticipates EU approval in the second half of 2012.
Veitch joins Savient with more than 24 years of pharmaceutical industry experience at Bristol- Myers Squibb and SmithKline Beecham Pharmaceuticals, and has extensive knowledge across many therapy areas including: oncology, virology, CV-Metabolism, CNS and immunology.
Most recently he was senior vice president of European marketing and brand commercialisation at Bristol Myers Squibb.
Prior to that, Veitch spent 10 years in a number of leadership positions at Bristol-Myers Squibb.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities
The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258
The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
Research & Development
Coriolis Pharma opens US headquarters and laboratory at Research Triangle Park in North Carolina
Biopharmaceutical services specialist Coriolis Pharma has launched its first US base at the Alexandria Centre for Advanced Technologies, offering North American clients direct access to formulation development, particle analysis and drug product characterisation services